Program

June 11, 2009

8:00 Registration
8:40 Gios Bernardi Welcome
8:45 David Livingston Focus & Goals

- Keynote Address: Tumorigenic potential is a common attribute in some cancers

AM, Session I - Metabolic Pathways as Targets

Moderator: S. Elmore

| | Bruce Spiegelman Discussion | – Transcriptional control o energy homeostasis |
|-------|--------------------------------|--|
| 10:40 | Coffee break | |
| | William Kaelin Discussion | 2-oxoglutarate-dependen dioxygenases as therapeu tic targets in cancer |
| 12:00 | Lunch | |

PM, Session II - Cell Death Interference

Moderator: G. Superti-Furga

| | Vishva Dixit Discussion | - Deubiquitinases as thera- peutic targets in cancer |
|-------|-------------------------------|---|
| | Gregory Verdine Discussion | Forget everything you ever heard about "undrug- gable" targets |
| 14:40 | Coffee break | |
| | Nika Danial Discussion | - Integration of glucose metabolism and apoptosis |
| | Steven Elmore Discussion | - Allowing sick cells to die: Targeting Bcl-2 family pro- teins to treat cancer |
| | Wilhelm Krek Discussion | - VHL: linking microtubu- les to primary cilia mainte- nance, chromosome stabili- ty and tumor suppression |
| | | |

17:25 Adjourn

3

The Pezcoller Symposia

Program

June 12, 2009

AM, Session III – Unexpected Outcomes of Targeting Signal Transduction Proteins

Moderator: P. Finan

| | Emilio Hirsch Discussion | – Genetic modeling of PI3K inhibition |
|-------|------------------------------|--|
| | David Sabatini Discussion | - The therapeutic potential of the mTOR pathway |
| 10:10 | Coffee break | |
| 10.20 | Thomas Roberts Discussion | - What lies beyond the first round of PI3 kinase inhibitors? |

11:15 Poster Session & Lunch

PM, Session IV - New Approaches to Target Finding

Moderator: E. Hirsch

| | Giulio Superti-Furga Discussion | Molecular networks and chemical proteomics: charting drug targets |
|-------|------------------------------------|--|
| | Peter Finan Discussion | - Dissecting pathways by chemical genetics |
| | William Hahn Discussion | Functional genomic approaches to identify cancer targets and co-dependencies |
| 15:30 | Coffee break | |
| | Inder Verma Discussion | - Mouse tumors using lentiviral vectors |
| | Todd Golub Discussion | - Genomic approaches to drug discovery |
| 17:25 | Adjourn | |
| 20:00 | Symposium Dinner | |

Program

June 13, 2009

12:40 Lunch

14:00 Adjourn

AM, Session V - Clinical Translation

Moderator: W. Kaelin

| 8:00 | Best Posters' Oral Presentations | |
|-------|-----------------------------------|---|
| , | Pier Paolo Pandolfi Discussion | - Targeting the cancer initiating cell for therapy |
| | Charles Sawyers Discussion | – Rethinking 24/7 target inhibition |
| 10:40 | Coffee break | |
| | Zaver Bhujwalla Discussion | Conventional imaging to guide therapy of unconventio- nal targets |
| | Robert Kerbel Discussion | - Some unexpected outcomes of therapeutically interfering with VEGF pathway function |
| 12:30 | David Livingston | - Concluding Remarks |

Invited Participants

Zaver Bhujwalla

Johns Hopkins Univ, Baltimore, MD

- Nika Danial

Dana Farber Cancer Inst, Boston, MA

- Vishva Dixit

Genentech, So San Francisco, CA

Steven Elmore

Abbott Laboratories, Abbott Park. IL

- Peter Finan

Novartis Inst for Biomedical Res, Cambridge, MA

- Todd Golub

Dana Farber Cancer Inst, Boston, MA

- William Hahn

Dana Farber Cancer Inst, Boston, MA

- Emilio Hirsch

Univ of Torino, Torino, Italy

- William Kaelin

Dana Farber Cancer Inst, Boston, MA

- Robert Kerbel

Univ of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

- Wilhelm Krek

Inst of Cell Biology, Zurich, Switzerland

David Livingston

Dana Farber Cancer Inst, Boston, MA

- Enrico Mihich

Roswell Park Cancer Inst, Buffalo NY

- Sean Morrison

Univ of Michigan Ctr for Stem Cell Biol, Ann Arbor, MI

The Pezcoller Symposia

5

The Pezcoller Symposia

6

The Pezcoller Symposia

Invited Participants

- Pier Paolo Pandolfi
 Harvard Medical School, Boston, MA
- Thomas Roberts
 Dana Farber Cancer Inst, Boston, MA
- David Sabatini
 Whitehead Inst for Biomed Res, Cambridge, MA
- Charles Sawyers
 Memorial Sloan Kettering Cancer Ctr, New York, NY
- Bruce Spiegelman
 Dana Farber Cancer Inst, Boston, MA
- Giulio Superti-Furga
 Ctr for Molecular Med, Austrian Academy of Sciences,
 Vienna, Austria
- Gregory Verdine
 Dana Farber Cancer Inst, Boston, MA
- Inder Verma
 Salk Inst for Biological Studies, La Jolla, CA

The Pezcoller Foundation

The Pezcoller Foundation is a non-profit organisation created in 1980 by Prof. Alessio Pezcoller (1896 - 1993), Chief Surgeon of Santa Chiara Hospital of Trento, Italy. The goal of the Foundation is to promote biomedical research.

Activities:

- PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR CANCER RESEARCH – 75.000 Euro: this prize is presented, every year, to a scientist who has made a major scientific discovery in the field of cancer.
- PEZCOLLER FOUNDATION-ECCO RECOGNITION FOR CONTRIBUTION TO ONCOLOGY – 30.000 Euro: this prize is presented, every two years to a single individual (scientist, clinician, nurse. etc.) for his/her professional life dedication to the improvement of cancer treatment, care and research.
- THE PEZCOLLER SYMPOSIA: a series of annual symposia promoting interactions among scientists working at the cutting edge of basic oncological sciences.
- PEZCOLLER SEMINARS: a series of educational meetings for Medical Doctors.
- PEZCOLLER FOUNDATION FELLOWSHIP: for professional updating in oncology.
- THE PEZCOLLER FOUNDATION JOURNAL: this periodical is published in order to provide a direct link, at six monthly intervals, between the Pezcoller Foundation and the international medical and scientific community.

This Symposium is supported by

- Fondazione Cassa di Risparmio di Trento e Rovereto
- Provincia autonoma di Trento
- Comune di Trento
- Comune di Rovereto

The Pezcoller Foundation Symposia

21st Pezcoller Symposium

Unconventional Therapeutic Targets in Cancer

Trento, Italy, June 11-13, 2009 Conference Hall of Fondazione Cassa di Risparmio di Trento e Rovereto, via Calepina 1 – 38100 Trento

Co-chairmen

David Livingston, Enrico Mihich and Pier Paolo Pandolfi

Program committee

David Livingston, Enrico Mihich, Pier Paolo Pandolfi, William Kaelin and Wilhelm Krek

The focus of the Symposium will be on identifying new targets for anticancer drugs action, and on utilizing new concepts and methods for drug design and development. The topics to be discussed will include protein/protein interactions, targeting transcription factors, targeting death pathways, new chemical screening of novel molecular targets, valid alternatives to known target proteins, and unexpected effects of disrupted angiogenesis. Each talk will be followed by an equal time for discussion thus providing ample opportunities for interactions and cross-fertilization among participants.

A session of posters in the areas discussed at the Symposium will be included.

Poster abstracts should be submitted to Enrico Mihich (Roswell Park Cancer Institute, Buffalo, NY, enrico.mihich@ roswellpark.org) on or before May 15, 2009 and will be reviewed for acceptance by the Co-chairmen.

For scientific matters contact Dr. Mihich (enrico.mihich@roswellpark.org) or Dr. Livingston (david_livingston@dfci.harvard.edu).

For local arrangements and travel matters contact Pezcoller Foundation secretariat office, Trento, Italy, Pezcoller@ pezcoller.it.

2

The Pezcoller Symposia